

The effect of probiotics in the prevention of atopic dermatitis in children: a systematic review and meta-analysis

Feina Wang^{1#}, Fangru Wu^{2#}, Hong Chen³, Bibo Tang⁴

¹Department of Pediatrics, People's Hospital of Wanning, Wanning, China; ²Department of Pharmacy, The Fourth People's Hospital of Haikou, Haikou, China; ³Department of Neonatal, People's Hospital of Wanning, Wanning, China; ⁴Department of Pediatrics, Hainan Western Central Hospital, Danzhou, China

Contributions: (I) Conception and design: F Wang, F Wu, B Tang; (II) Administrative support: B Tang; (III) Provision of study materials or patients: F Wang, F Wu, B Tang; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: F Wang, F Wu, B Tang; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

"These authors contributed equally to this work.

Correspondence to: Bibo Tang, Bachelor. Department of Pediatrics, Hainan Western Central Hospital, No. 2, Fubo East Road, Nadal Town, Danzhou 571700, China. Email: tangbibo2021@163.com.

Background: Probiotics have anti-inflammatory effects and can alleviate clinical symptoms of atopic dermatitis (AD) in children. However, the effects of probiotics on AD in children were controversial. This study aimed to evaluate the clinical efficacy of probiotics in the prevention of AD in children by a meta-analysis method.

Methods: Randomized controlled trials (RCTs) on probiotics in the prevention of AD in children performed at home and abroad were searched in the PubMed, Web of Science, China National Knowledge Infrastructure (CNKI), and Wanfang databases using a combination of subject terms and free terms. The retrieval time was from the establishment of the database to November 2022. Meta-analysis was performed by using Stata 14.0 software. The inclusion criteria were based on the Population, Intervention, Comparison, Outcomes and Study (PICOS) framework. (I) Participants: age ≤ 18 ; (II) Intervention: the intervention group received probiotics; (III) Control: the control group received placebo; (IV) Outcomes: AD; (V) the type of study: randomized control group. We collected the number of two groups and the number of AD in the included literatures. The I² statistic was employed to evaluate heterogeneity.

Results: Thirty-seven RCTs were eventually included, including 2,986 in the experimental group and 3,145 in the control group. The meta-analysis showed that probiotics were superior to placebo in the prevention of AD [risk ratio (RR) (95% confidence interval): 0.83 (0.73, 0.94), $I^2=65.2\%$]. The sub-group meta-analysis showed that the clinical efficacy of probiotics in the prevention of AD was more significant in the following groups: mothers and infants, before and after childbirth, *Lactobacillus rhamnosus* or mixed probiotics, follow-up time ≤ 2 years, and conducted in Europe.

Conclusions: Probiotic intervention may provide an effective means of preventing AD in children. However, due to the heterogeneity of the results of this study, the results need confirmation in follow-up studies.

Keywords: Probiotics; atopic dermatitis; prevention; meta-analysis

Submitted Mar 09, 2023. Accepted for publication Apr 23, 2023. Published online Apr 27, 2023. doi: 10.21037/tp-23-200 View this article at: https://dx.doi.org/10.21037/tp-23-200

Introduction

Atopic dermatitis (AD) is a relapsing, chronic, noninfectious, inflammatory skin disease characterized by persistent itching of the skin, with an incidence of up to 20% in children (1,2). In recent decades, the incidence of pediatric AD has been increasing every year in both developed and developing countries (3). The clinical manifestations of AD in children include eczema-like rashes, such as erythema, papules, and exudative lesions at specific sites (4). As a non-fatal skin disease, pediatric AD imposes a significant psychosocial burden on patients and their families. A previous study reported that children with AD are more likely to have allergies, asthma, and mental health problems (5). Infants and children with AD are often treated with topical corticosteroids, antihistamines, and even antibiotics (6). However, these drugs have some side effects, and AD symptoms may recur quickly after the treatment is stopped. Therefore, it is necessary to carry out relevant research on the prevention and treatment of AD in children.

A previous study found that the gut microbiota is closely related to the occurrence and development of various human diseases. The gut microbiota of newborns comes from customized meconium, which is the result of

Highlight box

Key findings

• In this study, the meta-analysis showed that probiotics can effectively prevent the occurrence of atopic dermatitis (AD). Further subgroup analysis showed that taking rhamnoselactobacillus probiotics and mixed bacteria before and after delivery could significantly prevent the incidence of AD.

What is known and what is new?

- When given in adequate amounts, probiotics can exert beneficial effects not only in the gastrointestinal tract but also in the gutbrain-skin axis. Previous studies have reported that probiotics have anti-inflammatory effects and may reduce gastrointestinal inflammation and the clinical symptoms of AD;
- The prevention effect of *Lactobacillus rhamnosus* and probiotics with mixed flora on AD is superior, which may be related to the reduction of intestinal microorganisms such as *bifidobacterium* and *Lactobacillus* in the intestines of children with AD.

What is the implication, and what should change now?

- AD in children can be prevented in clinical practice using probiotics, especially when given pre- and postnatally;
- Further subgroup analysis of probiotic dosage and supplementation time was not performed in this study, which can be explored later.

Wang et al. Probiotics in the prevention of AD in children

maternal intestinal translocation. The gut microbiota in the early stages of the body's life may play an important role in the occurrence of allergic diseases in the subsequent life cycle (7). Changing the microbiome of the body can effectively prevent and treat allergic diseases. According to the definition of the World Health Organization, probiotics are living microorganisms that have a beneficial effect on the host organism and help protect the host from harmful bacteria (7). When given in sufficient amounts, probiotics can exert beneficial effects not only in the gastrointestinal tract but also in the gut-brain-skin axis (8-10). Previous studies have reported that probiotics exert anti-inflammatory effects and can alleviate gastrointestinal inflammation and the clinical symptoms of AD (11). The levels of bifidobacteria and lactobacilli in the intestines of AD patients decreased, while the levels of Clostridium increased (11). However, previous research on probiotics for preventing AD has not yielded consistent results. Ou et al. found in a study of 191 pregnant women and newborns that oral probiotics can reduce the risk of AD in pregnant women, but there is no significant correlation with the risk of AD in newborns (12). However, Schmidt et al. conducted a randomized controlled experiment on 290 study subjects and found that oral probiotics can reduce the risk of AD in newborns (13). The heterogeneity of different research results may be related to differences in oral probiotic strains, probiotic combinations, study population, and treatment duration. In this study, we performed a metaanalysis to evaluate the efficacy of probiotics at home and abroad compared with placebo in the prevention of AD in children, aiming to provide a certain theoretical basis for the prevention of AD in children. We present the following article in accordance with the PRISMA reporting checklist (available at https://tp.amegroups.com/article/ view/10.21037/tp-23-200/rc).

Methods

Literature search strategy and inclusion and exclusion criteria

The search terms were based on the objectives of this study. The English and Chinese search terms were as follows: "infant", "children", "Atopic dermatitis", and "Probiotic". Based on the above search terms, a systematic search was carried out in the China National Knowledge Infrastructure (CNKI), Wanfang database, PubMed, and Web of Science databases, and the retrieval time was from the establishment of the database to November 10, 2022. A manual search was also performed of all relevant literature, including published reviews and meta-analyses.

The inclusion criteria were based on the Population, Intervention, Comparison, Outcomes and Study (PICOS) principle: (I) Study: the article is clearly indicated as a randomized controlled trial (RCT); (II) Participants: the age of the observation object is ≤ 18 years old; the observation object is clinically diagnosed with AD; (III) Intervention: the experimental group was treated with probiotics (including *Lactobacillus, Bifidobacterium, Lactobacillus rhamnosus*, or mixed microbial communities).; (IV) Comparison: the control group was treated with a placebo. (V) Outcome: the clinical diagnosis is AD. However, if multiple reports assessed the same group of patients, we only selected the latest complete report.

The exclusion criteria were as follows: (I) the subject of the study was not probiotics and pediatric AD; (II) there was no control group, the baseline balance of the components was poor, or the two groups were not comparable; (III) outcome: the evaluation indicators were not clear; (IV) duplicate or incomplete literature, such as literature with only an abstract but no full text and no contact with the author, or literature with missing specific data (the number of people in both groups and the occurrence of AD were not reported); (V) reviews or case reports.

Data extraction and quality assessment

Two researchers independently conducted a quality assessment and extracted the data, and any disagreements were resolved through third-party discussion. The following data were extracted from the studies included in this article: author, year, recipients of intervention, the timing of probiotic intervention, duration of probiotic intervention, type of probiotic, follow-up time, study region, and other information.

The risk of bias in the included studies was assessed using the Cochrane systematic review methods tool (Cochrane ROB Tool v1). The assessments included sequence generation, allocation sequence concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective outcome reporting, and other potential sources of bias (14). Each quality item was categorized as low risk of bias, high risk of bias, or unclear risk of bias. The evaluation for each entry involved assessing the risk of bias as 'Yes' (low risk), 'No' (high risk), or 'Not 733

available' (unclear risk) (15). Differences were resolved by consensus.

Statistical analysis

In this study, statistical analysis was performed using STATA 14.0 (Computer Resource Center, USA). Each effect size was represented by the risk ratio (RR) and its 95% confidence interval (95% CI). Heterogeneity testing was evaluated using I^2 (the proportion of heterogeneity variation to overall variation). When $I^2=0$, it indicates homogeneity and no heterogeneity between studies; $I^2 < 50\%$, with low heterogeneity. For cases where heterogeneity does not exist or is low, a fixed effects model is used for meta-analysis; $I^2 \ge 50\%$, with significant heterogeneity between studies, a random effects model was used for meta-analysis. Conduct subgroup analysis on the intervention target (mother and/ or infant), intervention timing (pre/post-natal), type of probiotics (Lactobacillus/Bifidobacterium, or Lactobacillus rhamnosus and mixed microbiota), intervention duration (<2 years/ \geq 2 years), and experimental region (Europe, Oceania, or Asia). The Harbor method is based on the statistics and variance of integral tests to correct linear regression, which can avoid the risk of adding Class 1 errors to the traditional publication bias detection method Egger test. The Harbord method was used to determine whether there was publication bias among the included studies. Heterogeneity was assessed using Rabe plots. If the circles on the Rabe diagram are distributed in a straight line, it indicates that the heterogeneity in meta-analysis is relatively small. Statistical analysis with P<0.05 indicates statistical significance.

Results

Literature search results and the basic characteristics of the included articles

A total of 786 studies were initially obtained, including 341 articles retrieved from PubMed, 258 from Web of Science, 18 from CNKI, and 169 from the Wanfang database. Of these, 118 studies were excluded by eliminating duplicate articles; 423 studies that do not align with the research topic were excluded by reading the titles, abstracts, and full texts and 128 studies, including comments, reviews, and case reports, were excluded. After reading the full texts and re-screening, excluding 31 studies that did not find the full text and 49 studies with incomplete clinical data (without



Figure 1 Literature screening flow chart. CNKI, China National Knowledge Infrastructure.

reporting the occurrence of AD in both groups). Finally, 37 articles were included in this meta-analysis, with 2,986 patients in the experimental group receiving probiotics and 3,145 patients in the control group. The literature screening process and results are shown in *Figure 1*.

The basic characteristics of the included studies are listed in *Table 1*. Among them, there were 19 studies involving mothers and infants as the intervention objects, seven studies with mothers as the intervention objects. and 11 studies with infants as the intervention objects. The intervention time was prenatal in one study, postpartum in 11 studies, and prenatal and postpartum in 25 studies. Moreover, 12 studies used *Lactobacillus rhamnosus* alone, eight studies used *Lactobacillus* alone, one study used *Bifidobacterium* as probiotics, and 16 studies utilized mixed probiotics. The study area included 24 studies in Europe, six studies in Asia, and seven studies in Oceania. The research conducted by Kalliomäki [2003] (25) and Kalliomäki [2007] (26) were follow-up studies of Kalliomäki [2001] (24); studies by Kuitunen [2009] (29) and Peldan [2017] (33) were follow-up studies of Kukkonen [2007] (30); studies by Wickens [2012] (46), Wickens [2013] (48), and Wickens [2018] (44) were follow-up studies of Wickens [2008] (47). Therefore, Kalliomäki [2003] (25), Kalliomäki [2007] (26), Kuitunen [2009] (29), Peldan [2017] (33), Wickens [2012] (46), Wickens [2013] (48), and Wickens [2018] (44) were excluded. Thirty studies were finally included in further analysis.

Quality assessment of the included studies

Table 2 shows that all of the studies had a low risk of bias in terms of the blinding of investigators and patients, and 23 studies had a low risk of bias in terms of the blinding of outcome measures. Only one of the 30 studies was unclear about the random method bias; the remaining 29 studies had a low risk of random method bias. Additionally, 17 studies had low risk of bias in terms of

Translational Pediatrics, Vol 12, No 4 April 2023

Table 1 Characteristics of the included studies

First author	Year	Intervention participants	Intervention timing	Intervention duration	Types of probiotics	Follow-up period	Region	Remarks
Abrahammson (16)	2013	Mothers and their infants	Prenatal and postpartum	From 4 weeks before the expected date of delivery to 12 months after delivery	Lactobacillus	7 years	Europe	_
Allen (17)	2014	Mothers and their infants	Prenatal and postpartum	From 4 weeks before the expected date of delivery to 6 months after delivery	Mixed probiotics: Lactobacillus salivarius, Lactobacillus paracasei, Bifidobacterium animalis subsp Lactobacillus and Bifidobacterium bifidum	2 years	Europe	-
Böttcher (18)	2008	Mothers and their infants	Prenatal and postpartum	From 4 weeks before the expected date of delivery to 12 months after delivery	Lactobacillus	2 years	Europe	-
Boyle (19)	2011	Mothers	Prenatal	From 4 weeks before the expected date of delivery to the delivery	Lactobacillus rhamnosus	1 years	Europe	-
Cabana (20)	2017	Infants	Postpartum	From birth to 6 months	Lactobacillus rhamnosus	2 years	Europe	-
Dotterud (21)	2010	Mothers	Prenatal and postpartum	From 4 weeks before the expected date of delivery to 3 months after delivery	Mixed probiotics	2 years	Europe	-
Huurre (22)	2008	Mothers and their infants	Prenatal and postpartum	From 3 months before the expected date of delivery to the end of breastfeeding	Mixed probiotics	1 year	Europe	-
Jensen (23)	2012	Infants	Postpartum	From birth to 6 months	Lactobacillus	1 years	Asia	-
Kalliomaki (24)	2001	Mothers and their infants	Prenatal and postpartum	From 2–4 weeks before the expected date of delivery to 6 months after delivery	Lactobacillus rhamnosus	2 years	Europe	-
Kalliomäki (25)	2003	Mothers and their infants	Prenatal and postpartum	From 2–4 weeks before the expected date of delivery to 6 months after delivery	Lactobacillus rhamnosus	4 years	Europe	A follow-up study by Kalliomaki [2001]
Kalliomäki (26)	2007	Mothers and their infants	Prenatal and postpartum	From 2–4 weeks before the expected date of delivery to 6 months after delivery	Lactobacillus rhamnosus	7 years	Europe	A follow-up study by Kalliomaki [2001]
Kim (27)	2010	Mothers and their infants	Prenatal and postpartum	From 8 weeks before the expected date of delivery to 6 months after delivery	Mixed probiotics	1 year	Asia	-

Table 1 (continued)

Wang et al. Probiotics in the prevention of AD in children

Table 1 (continued)

First author	Year	Intervention participants	Intervention timing	Intervention duration	Types of probiotics	Follow-up period	Region	Remarks
Kopp (28)	2008	Mothers and their infants	Prenatal and postpartum	From 6 weeks before the expected date of delivery to 6 months after delivery	Lactobacillus	2 years	Europe	-
Kuitunen (29)	2009	Mothers and their infants	Prenatal and postpartum	From 4 weeks before the expected date of delivery to 6 months after delivery	Lactobacillus rhamnosus	5 years	Europe	A follow-up study by Kukkonen [2007]
Kukkonen (30)	2007	Mothers and their infants	Prenatal and postpartum	From 2–4 weeks before the expected date of delivery to 6 months after delivery	Lactobacillus rhamnosus	2 years	Europe	-
Loo (31)	2014	Infants	Postpartum	From birth to 6 months	Mixed probiotics	5 years	Asia	-
Niers (32)	2009	Mothers and their infants	Prenatal and postpartum	From 6 weeks before the expected date of delivery to 12 months after delivery	Mixed probiotics	2 years	Europe	-
Ou (12)	2012	Mothers and their infants	Prenatal and postpartum	From 16 weeks before the expected date of delivery to 6 months after delivery	Lactobacillus rhamnosus	18 months	Asia	-
Peldan (33)	2017	Mothers and their infants	Prenatal and postpartum	From 2–4 weeks before the expected date of delivery to 6 months after delivery	Lactobacillus rhamnosus	10 years	Europe	A follow-up study by Kukkonen [2007]
Plummer (34)	2020	Infants	Postpartum	From birth to 1months after delivery	Mixed probiotics: Lactobacillus rhamnosus, Lactobacillus, Streptococcus thermophilus	1 years	Oceania	-
Prescott (35)	2008	Infants	Postpartum	From birth to 6 months	Lactobacillus	2.5 years	Oceania	-
Rautava (36)	2012	Mothers	Prenatal and postpartum	From 8 weeks before the expected date of delivery to 2 months after delivery	Lactobacillus rhamnosus	2 years	Europe	-
Rautava (37)	2002	Mothers and their infants	Prenatal and postpartum	From 2–4 weeks before the expected date of delivery to 6 months after delivery	Lactobacillus rhamnosus	2 years	Europe	-
Rø (38)	2017	Mothers	Prenatal and postpartum	From 4 weeks before the expected date of delivery to 3 months after delivery	Mixed probiotics: Lactobacillus rhamnosus and Bifidobacterium	2 years	Europe	-

Table 1 (continued)

Translational Pediatrics, Vol 12, No 4 April 2023

Table 1 (continued)

First author	Year	Intervention participants	Intervention timing	Intervention duration	Types of probiotics	Follow-up period	Region	Remarks
Rozé (39)	2012	Infants	Postpartum	From birth to 6 months	Mixed probiotics: Lactobacillus rhamnosus and Bifidobacterium	6 months	Europe	-
Schmidt (13)	2019	Infants	Postpartum	8–14 months	Mixed probiotics: Lactobacillus rhamnosus and Bifidobacterium	6 months	Europe	-
Simpson (40)	2015	Mothers	Prenatal and postpartum	From 4 weeks before the expected date of delivery to 3 months after delivery	Mixed probiotics: Lactobacillus rhamnosus, Lactobacillus acidophilus and Bifidobacterium animalis	6 years	Europe	-
Taylor (41)	2007	Infants	Postpartum	From birth to 6 months	Lactobacillus	5 years	Europe	-
West (42)	2009	Infants	Postpartum	4–13 months	Lactobacillus	4-13 months	Europe	-
West (43)	2013	Infants	Postpartum	4–13 months	Lactobacillus	9 years	Europe	-
Wickens (44)	2018	Mothers and their infants	Prenatal and postpartum	From 4 weeks before the expected date of delivery to 2 years after delivery	Mixed probiotics: Lactobacillus rhamnosus and Bifidobacterium	11 years	Oceania	A follow-up study by Wickens [2008]
Wickens (45)	2018	Mothers	Prenatal and postpartum	From 24 weeks before the expected date of delivery to 6 months after delivery	Lactobacillus rhamnosus	1 years	Oceania	-
Wickens (46)	2012	Mothers and their infants	Prenatal and postpartum	From 4 weeks before the expected date of delivery to 2 years after delivery	Mixed probiotics: Lactobacillus rhamnosus and Bifidobacterium animalis	4 years	Oceania	A follow-up study by Wickens [2008]
Wickens (47)	2008	Mothers and their infants	Prenatal and postpartum	From 4 weeks before the expected date of delivery to 2 years after delivery	Mixed probiotics: Lactobacillus rhamnosus and Bifidobacterium animalis	2 years	Oceania	-
Wickens (48)	2013	Mothers and their infants	Prenatal and postpartum	From 4 weeks before the expected date of delivery to 2 years after delivery	Mixed probiotics: Lactobacillus rhamnosus and Bifidobacterium animalis	6 years	Oceania	A follow-up study by Wickens [2008]
Han (49)	2019	Infants	Postpartum	3 days to 10 days after birth	Mixed probiotics: Bifidobacterium, Lactobacillus, Streptococcus thermophilus	1 months	Asia	-
Wu (50)	2010	Mothers	Prenatal and postpartum	From 4 weeks before the expected date of delivery to the end of breastfeeding	Bifidobacterium	2 years	Asia	-

Blinding methods Selective Sequence Allocation sequence Other potential Incomplete First author Year outcome Researchers Outcome generation concealment outcome data sources of bias reporting and patients measurers Kalliomaki 2001 Not available Yes Yes Yes No Yes Yes Rautava 2002 Yes Not available Yes No Yes Yes Yes Kukkonen 2007 Yes Not available Yes Yes No Yes Yes Taylor 2007 Yes Yes Yes Yes Not available No Not available 2008 Böttcher Not available Yes Yes Not available Yes Yes No Huurre 2008 Yes Not available Yes Yes No Yes Yes 2008 Kopp Yes Not available Yes Yes Yes Yes Yes 2008 Not available Prescott Yes Yes Yes Yes Yes No Wickens 2008 Yes Not available Yes Yes No Yes Yes Niers 2009 Not available Yes Yes Not available Not available Yes No West 2009 Not available Yes Yes Yes Yes Yes No Dotterud 2010 Yes Not available Yes Yes No Yes Yes Kim 2010 Not available Yes Yes Yes Yes Yes No Wu 2010 Not available Yes Yes Yes Not available Yes No 2011 Yes Not available Boyle Yes Yes Yes Yes No 2012 Not available Jensen Yes Yes Not available Not available Yes No 2012 Ou Yes Not available Yes Not available No Yes Yes 2012 Rautava Yes Not available Yes Yes No Yes Yes Roze 2012 Not available Yes Yes Yes Yes Yes No Abrahammson 2013 Yes Yes Yes Not available Not available No Not available Not available West 2013 Yes Yes Yes Not available Yes No 2014 Not available Allen Yes Yes Yes Yes Yes No Loo 2014 Yes Not available Not available Yes No Not available Yes Simpson 2015 Yes Not available Yes No Yes No Yes Cabana 2017 Not available Not available Yes Yes Yes Yes No Rø 2017 Yes Yes Yes Yes Yes Yes Yes Wickens 2018 Yes Yes Yes Yes Yes Yes Yes Schmidt 2019 Not available Yes Yes Yes Yes Yes Yes Han 2019 Yes Not available Yes Yes Not available Yes Yes 2020 Yes Yes Yes Plummer Yes Yes Yes Yes

Table 2 Risk of bias assessment of the included studies

	Risk Ratio	%
Study	(95% CI)	Weight
Kalliomaki, 2001	0.51 (0.31, 0.86)	3.44
Rautava, 2002	0.32 (0.12, 0.85)	1.39
Kukkonen, 2007	0.64 (0.52, 0.79)	6.40
Taylor, 2007	1.14 (0.67, 1.92)	3.38
Bottcher, 2008	1.15 (0.71, 1.87)	3.65
Huurre, 2008	0.55 (0.23, 1.32)	1.68
Kopp, 2008	1.03 (0.53, 1.98)	2.55
Prescott, 2008	1.27 (0.84, 1.94)	4.24
Wickens, 2008	0.66 (0.47, 0.92)	5.04
Niers, 2009	0.42 (0.18, 0.99)	1.70
West, 2009	0.49 (0.24, 1.02)	2.18
Dotterud, 2010	3.23 (1.58, 6.60)	2.27
Kim, 2010	0.53 (0.26, 1.12)	2.15
Wu, 2010	0.71 (0.37, 1.35)	2.58
Boyle, 2011	0.94 (0.53, 1.68)	3.02
Jensen, 2012	- 1.91 (0.94, 3.86)	2.30
Ou, 2012	- 1.45 (0.55, 3.84)	1.41
Rautava, 2012	0.41 (0.27, 0.60)	4.46
Rozé, 2012	0.41 (0.08, 2.00)	0.59
Abrahammson, 2013	1.04 (0.73, 1.47)	4.92
West, 2013	0.66 (0.27, 1.58)	1.66
Allen, 2014	0.95 (0.81, 1.12)	6.91
Loo, 2014	0.80 (0.53, 1.19)	4.38
Simpson, 2015	0.95 (0.83, 1.09)	7.16
Cabana, 2017	0.79 (0.55, 1.15)	4.68
Wickens, 2018	0.85 (0.57, 1.26)	4.47
Schmidt, 2019	0.97 (0.88, 1.07)	7.43
Han, 2019	0.54 (0.31, 0.93)	3.19
Plummer, 2020	2.32 (0.59, 9.08)	0.79
Overall, DL (l ² = 65.2%, p = 0.000)	0.83 (0.73, 0.94)	100.00
0.0625 1	16	

Figure 2 Forest plot of probiotic interventions for the prevention of pediatric atopic dermatitis. CI, confidence interval; DL, deep learning.

allocation concealment, 17 studies had a low risk of bias for completeness of outcome data, 15 studies had a low risk of bias in terms of the reported outcomes of selective studies, and 12 studies had a low risk of other bias.

Effect of probiotics on AD prevention

As shown in *Figure 2*, the heterogeneity test results showed that P<0.001, $I^2=65.2\%$ and $P_{heterogeneity}<0.001$, indicating that there is heterogeneity among these studies, which may originate from 49 studies with different intervention subjects, intervention timing, and probiotic dosage. Using the random effect model, the pooled effect size results showed that probiotic intervention has a significant effect on the prevention of AD [RR (95% CI) =0.83 (0.73, 0.94)].

Subgroup analysis

Subgroup analysis was carried out for the intervention object, follow-up time, intervention probiotic species, intervention duration and trial region.

In the subgroup analysis on the intervention objects (shown in *Figure 3*), probiotic intervention had a significant effect on the prevention of AD [RR (95% CI) =0.65 (0.49, 0.86), I²=49.3%, P_{heterogeneity}=0.027] when the intervention recipients were mothers and infants. When the patients were mothers or infants, probiotic intervention had no significant effect on preventing AD [RR (95% CI) =0.69 (0.38, 1.26), I²=79.7%, P_{heterogeneity}<0.001; RR (95% CI) =0.85 (0.62, 1.17), I²=44.7%, P_{heterogeneity}=0.054].

In the subgroup analysis on the timing of the intervention (shown in *Figure 4*), the effect of probiotic intervention on

	Risk Ratio	%
Group 1 and Study	(95% CI)	Weight
mothers and infants		
Kalliomaki, 2001	0.37 (0.17, 0.77)	3.46
Rautava, 2002	0.20 (0.06, 0.72)	1.84
Kukkonen, 2007	0.54 (0.40, 0.72)	5.66
Bottcher, 2008	1.25 (0.57, 2.76)	3.29
Huurre, 2008	0.50 (0.19, 1.36)	2.56
Корр, 2008	1.04 (0.42, 2.57)	2.86
Wickens, 2008	0.53 (0.32, 0.88)	4.63
Niers, 2009	0.34 (0.12, 0.95)	2.42
Kim, 2010	0.43 (0.16, 1.14)	2.62
Ou, 2012	- 1.53 (0.51, 4.58)	2.27
Abrahammson, 2013	1.06 (0.59, 1.92)	4.21
Allen, 2014	0.89 (0.61, 1.30)	5.27
Subgroup, DL (l ² = 49.3%, p = 0.027)	0.65 (0.49, 0.86)	41.09
infants		
Taylor 2007	1 18 (0 60 2 36)	373
Prescott 2008	1.47 (0.76, 2.86)	3.84
West 2009	0 43 (0 18, 1 01)	3.03
Jensen 2012	2 31 (0 94 5 64)	2 90
Rozé 2012	0.38 (0.07, 2.08)	1.20
West 2013	0.61 (0.22, 1.70)	2.48
	0.73 (0.42, 1.77)	4 35
Cabana 2017	0.69 (0.38, 1.26)	4 16
Schmidt 2019	0.81 (0.43, 1.55)	3.93
Han 2019	0.46(0.23, 0.90)	3.80
Plummer 2020	2 39 (0 59 9 79)	1.60
Subgroup, DL (l ² = 44.7%, p = 0.054)	0.85 (0.62, 1.17)	35.02
Dotterud 2010	5 14 (1 57 16 88)	2 04
Wu 2010	0.58 (0.22, 1.57)	2.58
Boyle 2011	0.93 (0.46, 1.88)	3.66
Bautava 2012	0.17 (0.08, 0.35)	3.48
Simpson 2015	0.86 (0.57, 1.30)	5 11
Bo 2017	0.30 (0.10, 0.89)	2 32
Wickens 2018	0.81 (0.50, 1.33)	1 70
Subgroup DL $(l^2 = 79.7\% \text{ p} = 0.000)$	0.69 (0.38, 1.35)	23.80
Subgroup, DE (1 - 79.176, p = 0.000)	0.03 (0.30, 1.20)	25.05
Heterogeneity between groups: p = 0.460		
Overall, DL ($I^2 = 59.9\%$, p = 0.000)	0.72 (0.59, 0.88)	100.00
0.0625	16	

Figure 3 Subgroup analysis of probiotic interventions for the prevention of atopic dermatitis in children (grouped by intervention subject). CI, confidence interval; DL, deep learning.

the prevention of AD was significant [RR (95% CI) =0.64 (0.49, 0.85), I^2 =66.6%, $P_{heterogeneity}$ <0.001] when the timing of the intervention was prenatal and postpartum. However, when it was prenatal or postpartum, probiotic intervention had no significant effect on the prevention of AD [RR (95% CI) =0.93 (0.46, 1.88), I^2 =0.0%; RR (95% CI) =0.85 (0.62, 1.17), I^2 =44.7%, $P_{heterogeneity}$ =0.054].

In subgroup analysis on the types of probiotics (shown in *Figure 5*), the effect of probiotic intervention on the prevention of AD was significant [RR (95% CI) =0.54 (0.36, 0.80), I^2 =68.2%, P_{heterogeneity}=0.003; RR (95% CI) =0.70 (0.52, 0.93), I²=52.4%, P_{heterogeneity}=0.014] when the types of probiotics were *Lactobacillus rhamnosus* and mixed flora; however, when the probiotics were *Lactobacillus* or *Bifidobacterium*, the effect of probiotic intervention on the prevention of AD was not significant [RR (95% CI) =1.09 (0.79, 1.49), I²=25.7%, P_{heterogeneity}=0.224; RR (95% CI) =0.58 (0.22, 1.57), I²=0.0%].

In subgroup analysis on the trial region (shown in *Figure 6*), probiotic intervention had a significant effect on the prevention of AD [RR (95% CI) =0.66 (0.51, 0.86), I^2 =63.2%, P_{heterogeneity}<0.001] when the trial region was

Group 2 and Study (95% Cl) Weig Before and after childbirth 0.37 (0.17, 0.77) 3.4 Rautava, 2002 0.54 (0.40, 0.72) 1.6 Kukkonen, 2007 0.54 (0.40, 0.72) 1.6 Bottcher, 2008 0.55 (0.19, 1.36) 2.5 Huurre, 2008 0.53 (0.19, 1.36) 2.5 Wickens, 2008 0.53 (0.12, 0.95) 2.4 Niers, 2008 0.53 (0.32, 0.88) 4.6 Niers, 2009 0.44 (0.42, 2.57) 2.5 Outerud, 2010 0.43 (0.16, 1.14) 2.6 Wu, 2010 0.43 (0.16, 1.14) 2.6 Wu, 2010 0.43 (0.16, 1.14) 2.6 Wathammson, 2013 1.06 (0.59, 1.92) 4.2 Allen, 2014 0.88 (0.22, 1.57) 2.5 Simpson, 2015 0.80 (0.57, 1.30) 5.5 Roz, 2017 0.86 (0.57, 1.30) 5.1 After childbirth 1.18 (0.60, 2.36) 3.7 Taylor, 2007 1.18 (0.60, 2.36) 3.7 Prescott, 2008 0.43 (0.18, 1.01) 3.3 Jansen, 2012 0.38 (0.47, 2.48) 2.6 Rozé, 2012 0.83 (0.47, 2.48) 2.6 West, 2013 0.64 (0.49, 0.85) 61.3 Loo, 2014 0.38 (0.47, 2.48) 2.6<		Risk Ratio	%
Before and after childbirth Kalliomaki, 2001 Rautava, 2002 Bottcher, 2008 Huure, 2008 Wickens, 2008 Wickens, 2008 Niers, 2009 Dotterud, 2010 Wickens, 2010 Wu, 2010 U, 2012 Rautava, 2012 Abrahammson, 2013 Alten, 2014 Alten, 2014 Mickens, 2015 Ro, 2017 Ro, 2018 Rote, 2018 Rote, 2012 Rote, 2012 Rote, 2012 Rote, 2012 Rote, 2012 Rote, 2012 Rote, 2012 Rote, 2012 Rote, 2014 Rote, 2014 Rote, 2014 Rote, 2019 Rote, 2014 Rote, 2017 Rote, 2014 Rote, 2014 Rote, 2017 Rote, 2017 Rote, 2017 Rote, 2017 Rote, 2018 Rote, 2012 Rote, 2014 Rote, 2017 Rote, 2017 Rote, 2018 Rote, 2017 Rote, 2018 Rote, 2012 Rote, 2014 Rote, 2019 Rote, 2014 Rote, 2017 Rote, 2014 Rote, 2017 Rote, 2014 Rote, 2017 Rote, 2014 Rote, 2017 Rote, 2018 Rote, 2017 Rote, 2018 Rote, 2017 Rote, 2017 Rote, 2018 Rote, 2017 Rote, 2018 Rote, 2017 Rote, 2018 Rote, 2017 Rote, 2018 Rote, 2017 Rote, 2019 Rote, 2014 Rote, 2019 Rote, 2014 Rote, 2015 Rote, 2017 Rote, 2018 Rote, 2017 Rote, 2018 Rote, 2017 Rote, 2018 Rote, 2017 Rote, 2018 Rote, 2017 Rote, 2018 Rote, 2018 R	Group 2 and Study	(95% CI)	Weight
Kalliomaki, 2001 Rautava, 2002 Kukkonen, 2007 Bottcher, 2008 Huurre, 2008 Wickens, 2009 Dotterud, 2010 Wickens, 2009 Unit (15, 2010 Wu, 2010 Unit (15, 2012 Unit (15, 2014) Abrahammson, 2013 Allen, 2014 Subgroup, DL (I ² = 66.6%, p = 0.000) After childbirth Taylor, 2007 Huurre, 2020 Subgroup, DL (I ² = 66.6%, p = 0.000) Rautava, 2012 After childbirth Taylor, 2007 Huurre, 2020 Subgroup, DL (I ² = 0.0%, p = 0.000) Before childbirth Boyle, 2011 Subgroup, DL (I ² = 0.0%, p = 0.000) DOTE Heterogeneity between groups: p = 0.355 Overall, DL (I ² = 59.9%, p = 0.000) DOTE D	Before and after childbirth		
Rautava, 2002 Kukkoen, 2007 Bottcher, 2008 Huure, 2008 Huure, 2008 Kopp, 2008 Uniers, 2008 Wickens, 2008 Wickens, 2008 Wickens, 2009 Dotterud, 2010 Kim, 2010 Wu, 2010 Wu, 2010 Wu, 2010 Wu, 2010 Wu, 2010 U, 2012 Rautava, 2012 Abrahammson, 2013 Allen, 2014 Simpson, 2015 Ro, 2017 Wickens, 2018 Alter childbirth Taylor, 2007 Prescott, 2008 Mest, 2009 U, 2012 Rozé, 2012 Wickens, 2018 After childbirth Taylor, 2007 Han, 2019 Pummer, 2020 Subgroup, DL (l ² = 66.6%, p = 0.000) After childbirth Taylor, 2007 Han, 2019 Pummer, 2020 Subgroup, DL (l ² = 44.7%, p = 0.054) Before childbirth Boyle, 2011 Subgroup, DL (l ² = 0.0%, p = .) DOPE DOPE 1	Kalliomaki, 2001	0.37 (0.17, 0.77)	3.46
Kukkonen, 2007 0.54 (0.40, 0.72) 5.6 Bottchr, 2008 1.25 (0.57, 2.76) 3.2 Huurre, 2008 0.50 (0.19, 1.36) 2.5 Wickens, 2008 0.53 (0.32, 0.88) 4.6 Niers, 2009 0.34 (0.12, 0.95) 2.5 Dotterud, 2010 5.14 (1.57, 16.88) 2.0 Kim, 2010 0.43 (0.16, 1.14) 2.6 Wu, 2010 0.43 (0.16, 1.14) 2.6 Wu, 2011 0.43 (0.16, 1.48) 2.0 Ou, 2012 Rautava, 2012 1.53 (0.51, 4.58) 2.4 Abrahammson, 2013 1.06 (0.59, 1.92) 4.2 Allen, 2014 0.88 (0.57, 1.30) 5.1 Subgroup, DL (I ² = 66.6%, p = 0.000) 0.84 (0.49, 0.85) 61.3 After childbirth 1.18 (0.60, 2.36) 3.7 Taylor, 2007 1.18 (0.60, 2.36) 3.7 Prescott, 2008 0.33 (0.07, 2.08) 1.3 Vest, 2013 0.61 (0.22, 1.70) 2.4 Loo, 2014 0.33 (0.07, 2.08) 1.3 Cabana, 2017 0.85 (0.62, 1.17) 3.6 West, 2013 0.69 (0.38, 1.26) 4.1	Rautava, 2002	0.20 (0.06, 0.72)	1.84
Bottcher, 2008 Huure, 2008 Kopp, 2008 Wickens, 2008 Niers, 2009 Dotterud, 2010 Win, 2010 Ou, 2012 Rautava, 2012 Abrahammson, 2013 Allen, 2014 Subgroup, DL (l ² = 66.6%, p = 0.000) After childbirth Taylor, 2007 Prescott, 2008 West, 2009 Uter 2012 Rate childbirth Taylor, 2007 Prescott, 2008 West, 2019 Cabena, 2017 Subgroup, DL (l ² = 66.6%, p = 0.000) After childbirth Taylor, 2007 Prescott, 2008 West, 2019 Cabena, 2017 Subgroup, DL (l ² = 66.6%, p = 0.000) After childbirth Taylor, 2007 Prescott, 2008 West, 2019 Cabena, 2017 Subgroup, DL (l ² = 66.6%, p = 0.000) After childbirth Taylor, 2007 Prescott, 2008 West, 2019 Han, 2019 Han, 2019 Plummer, 2020 Subgroup, DL (l ² = 60.6%, p = 0.000) After childbirth Boyle, 2011 Subgroup, DL (l ² = 60.6%, p = 0.000) After childbirth Boyle, 2012 Subgroup, DL (l ² = 66.6%, p = 0.000) After childbirth Boyle, 2014 Cabena, 2017 Subgroup, DL (l ² = 60.6%, p = 0.005) Defer	Kukkonen, 2007	0.54 (0.40, 0.72)	5.66
Huurre, 2008 Kopp, 2008 Wickens, 2008 Wickens, 2009 Dotterud, 2010 Kim, 2010 U, 2012 Rautava, 2012 Alten, 2014 Simpson, 2015 Ro, 2017 Wickens, 2018 Alter, 2014 Subgroup, DL (I ² = 66.6%, p = 0.000) After childbirth Taylor, 2007 The sect, 2008 West, 2013 Long 2017 Subgroup, DL (I ² = 44.7%, p = 0.054) Before childbirth Boyle, 2011 Subgroup, DL (I ² = 60.9%, p = 0.000) Deces Heterogeneity between groups: p = 0.355 Overall, DL (I ² = 59.9%, p = 0.000) Deces Deces Long 2017 Deces Long 2017 Deces L	Bottcher, 2008	1.25 (0.57, 2.76)	3.29
Kopp, 2008 1.04 (0.42, 2.57) 2.6 Wickens, 2009 0.34 (0.12, 0.95) 2.4 Dotterud, 2010 5.14 (1.57, 16.88) 2.0 Kim, 2010 0.43 (0.16, 1.14) 2.6 Wu, 2010 0.43 (0.16, 1.14) 2.6 Wu, 2010 0.58 (0.22, 1.57) 2.5 Ou, 2012 1.53 (0.51, 4.58) 2.7 Rautava, 2012 1.53 (0.51, 4.58) 2.6 Abrahammson, 2013 1.06 (0.59, 1.92) 4.2 Allen, 2014 0.89 (0.61, 1.30) 5.5 Simpson, 2015 0.86 (0.57, 1.30) 5.1 Ro, 2017 0.30 (0.10, 0.89) 2.3 Wickens, 2008 0.64 (0.49, 0.85) 61.3 After childbirth 1.18 (0.60, 2.36) 3.7 Teyscott, 2008 1.47 (0.76, 2.86) 3.6 West, 2009 0.43 (0.18, 1.01) 3.0 Jensen, 2012 0.38 (0.07, 2.08) 1.1 Rozé, 2012 0.38 (0.07, 2.08) 1.1 West, 2013 0.61 (0.22, 1.70) 2.4 Cabana, 2017 0.89 (0.81, 1.55) 3.6 Subgroup, DL (l ² = 44.7%, p = 0.054)	Huurre, 2008	0.50 (0.19, 1.36)	2.56
Wickens, 2008 Niers, 2009 Dotterud, 2010 Kim, 2010 Ou, 2012 Rautava, 2012 Abrahammson, 2013 Allen, 2014 Simpson, 2015 Ro, 2017 Subgroup, DL ($f^2 = 66.6\%$, p = 0.000) After childbirth Taylor, 2007 Prescott, 2008 West, 2009 Usest, 2019 Cabana, 2017 Conditional and the set of the	Kopp, 2008	1.04 (0.42, 2.57)	2.86
Niers, 2009 Dotterud, 2010 Kim, 2010 Ou, 2012 Rautava, 2012 Abrahammson, 2013 Allen, 2014 Simpson, 2015 Ro, 2017 Subgroup, DL (l ² = 66.6%, p = 0.000) After childbirth Taylor, 2007 After childbirth Taylor, 2007 After childbirth Taylor, 2012 Rozé, 2014 Cabana, 2017 Subgroup, DL (l ² = 44.7%, p = 0.054) Before childbirth Boyle, 2011 Subgroup, DL (l ² = 60.0%, p = .) Before childbirth Boyle, 2011 Before childbirth Boyle, 2011 Before childbirth Boyle, 2011 Rozé, 2012 Rozé, 2014 Rozé, 2014 Rozé, 2017 Rozé, 2017 Rozé, 2017 Rozé, 2017 Rozé, 2017 Rozé, 2017 Rozé, 2017 Rozé, 2017 Rozé, 2017 Rozé, 2014 Rozé, 2017 Rozé, 2018 Rozé, 2011 Rozé, 2011 Rozé, 2011 Rozé, 2011 Rozé, 2011 Rozé, 2011 Rozé, 2014 Rozé, 2011 Rozé, 2014 Rozé, 2011 Rozé, 2014 Rozé, 2011 Rozé, 2014 Rozé, 2011 Rozé, 2014 Rozé, 2014 Rozé, 2014 Rozé, 2015 Rozé, 2017 Rozé, 2018 Rozé, 2017 Rozé, 2018 Rozé, 2017 Rozé, 2018 Rozé, 2017 Rozé, 2018 Rozé, 2017 Rozé, 2018 Rozé, 2019 Rozé, 2018 Rozé, 2017 Rozé, 2018 Rozé, 2019 Rozé, 2018 Rozé, 2019 Rozé, 2018 Rozé, 2019 Rozé, 2010 Rozé, 2019 Rozé, 2010 Rozé, 2010 Rozé, 2010 Rozé, 2010 Rozé, 2010 Rozé, 2010 Rozé, 2010 Rozé, 2010	Wickens, 2008	0.53 (0.32, 0.88)	4.63
Dotterud, 2010 5.14 (1.57, 16.88) 2.0 Kim, 2010 0.43 (0.16, 1.14) 2.6 Wu, 2010 0.58 (0.22, 1.57) 2.5 Ou, 2012 1.53 (0.51, 4.58) 2.2 Rautava, 2012 1.53 (0.51, 4.58) 2.2 Abrahammson, 2013 1.06 (0.59, 1.92) 4.2 Allen, 2014 0.89 (0.61, 1.30) 5.2 Simpson, 2015 0.86 (0.57, 1.30) 5.1 Ro, 2017 0.30 (0.10, 0.89) 2.3 Wickens, 2018 0.81 (0.50, 1.33) 4.7 Subgroup, DL (l² = 66.6%, p = 0.000) 0.64 (0.49, 0.85) 61.3 After childbirth 7aylor, 2007 1.18 (0.60, 2.36) 3.7 Prescott, 2008 1.47 (0.76, 2.86) 3.8 West, 2009 0.43 (0.18, 1.01) 3.0 Jensen, 2012 0.83 (0.07, 2.08) 1.2 Rozé, 2012 0.83 (0.07, 2.08) 3.6 Vest, 2013 0.61 (0.22, 1.70) 2.4 Loo, 2014 0.83 (0.64, 1.88) 3.6 Subgroup, DL (l² = 44.7%, p = 0.054) 0.85 (0.62, 1.17) 35.6 Subgroup, DL (l² = 0.0%, p = .) 0.93 (0.46, 1.88	Niers, 2009	0.34 (0.12, 0.95)	2.42
Kim, 2010 0.43 (0.16, 1.14) 2.6 Wu, 2010 0.58 (0.22, 1.57) 2.5 Ou, 2012 1.53 (0.51, 4.58) 2.2 Rautava, 2012 0.17 (0.06, 0.35) 3.4 Abrahammson, 2013 1.06 (0.59, 1.92) 4.2 Allen, 2014 0.89 (0.61, 1.30) 5.5 Simpson, 2015 0.86 (0.57, 1.30) 5.1 Ro, 2017 0.30 (0.10, 0.89) 2.3 Wickens, 2018 0.81 (0.50, 1.33) 4.7 Subgroup, DL (1 ² = 66.6%, p = 0.000) 0.64 (0.49, 0.85) 61.3 After childbirth 7 0.30 (0.10, 0.89) 2.3 Rozé, 2012 0.64 (0.49, 0.85) 61.3 Mest, 2009 0.43 (0.18, 1.01) 3.6 Jensen, 2012 0.38 (0.07, 2.08) 1.1 Rozé, 2012 0.38 (0.07, 2.08) 1.2 West, 2013 0.61 (0.22, 1.70) 2.4 Loo, 2014 0.73 (0.42, 1.27) 4.3 Schmidt, 2019 0.81 (0.43, 1.55) 3.5 Han, 2019 0.44 (0.23, 0.90) 3.8 Subgroup, DL (1 ² = 0.0%, p = .) 0.93 (0.46, 1.88) 3.6	Dotterud, 2010	5.14 (1.57, 16.88)	2.04
Wu, 2010 0.58 (0.22, 1.57) 2.5 Ou, 2012 1.53 (0.51, 4.58) 2.2 Rautava, 2012 0.17 (0.08, 0.35) 3.4 Abrahammson, 2013 1.06 (0.59, 1.92) 4.2 Allen, 2014 0.89 (0.61, 1.30) 5.2 Simpson, 2015 0.86 (0.57, 1.30) 5.1 Ro, 2017 0.30 (0.10, 0.89) 2.3 Wickens, 2018 0.81 (0.50, 1.33) 4.7 Subgroup, DL (l ² = 66.6%, p = 0.000) 0.64 (0.49, 0.85) 61.3 After childbirth 1.18 (0.60, 2.36) 3.7 Prescott, 2008 1.47 (0.76, 2.86) 3.6 West, 2013 0.61 (0.22, 1.70) 2.4 Loo, 2014 0.73 (0.42, 1.27) 4.3 Cabana, 2017 0.69 (0.38, 1.26) 4.4 Schmidt, 2019 0.85 (0.62, 1.17) 35.6 Han, 2019 0.86 (0.23, 0.90) 3.6 Plummer, 2020 2.39 (0.46, 1.88) 3.6 Subgroup, DL (l ² = 0.0%, p = .) 0.93 (0.46, 1.88) 3.6 Heterogeneity between groups: p = 0.355 0.72 (0.59, 0.88) 100.0	Kim 2010	0 43 (0 16 1 14)	2 62
Ou, 2012 153 (0.51, 4.58) 2.2 Rautava, 2012 0.17 (0.08, 0.35) 3.4 Abrahammson, 2013 1.06 (0.59, 1.92) 4.2 Allen, 2014 0.89 (0.61, 1.30) 5.2 Simpson, 2015 0.86 (0.57, 1.30) 5.1 Ro, 2017 0.30 (0.10, 0.89) 2.3 Wickens, 2018 0.81 (0.50, 1.33) 4.7 Subgroup, DL (l ² = 66.6%, p = 0.000) 0.64 (0.49, 0.85) 61.3 After childbirth 7 1.18 (0.60, 2.36) 3.7 Prescott, 2008 1.47 (0.76, 2.86) 3.6 West, 2013 0.43 (0.18, 1.01) 3.0 Jonsen, 2012 0.38 (0.07, 2.08) 1.2 Kozé, 2012 0.38 (0.07, 2.08) 1.2 West, 2013 0.61 (0.22, 1.70) 2.4 Loo, 2014 0.69 (0.38, 1.26) 4.1 Cabana, 2017 0.69 (0.38, 1.26) 4.1 Subgroup, DL (l ² = 44.7%, p = 0.054) 0.85 (0.62, 1.17) 35.0 Before childbirth 0.93 (0.46, 1.88) 3.6 Subgroup, DL (l ² = 0.0%, p = .) 0.93 (0.46, 1.88) 3.6 Uproverall, DL (l ² = 59.9%, p = 0.000) </td <td>Wu 2010</td> <td>0.58 (0.22, 1.57)</td> <td>2 58</td>	Wu 2010	0.58 (0.22, 1.57)	2 58
Col, Dot Col, Dot <t< td=""><td>Qu 2012</td><td>1 53 (0 51 4 58)</td><td>2 27</td></t<>	Qu 2012	1 53 (0 51 4 58)	2 27
Abrahammson, 2013 1.06 (0.59, 1.92) 4.2 Allen, 2014 0.89 (0.61, 1.30) 5.2 Simpson, 2015 0.86 (0.57, 1.30) 5.1 Ro, 2017 0.30 (0.10, 0.89) 2.3 Wickens, 2018 0.81 (0.50, 1.33) 4.7 Subgroup, DL (l ² = 66.6%, p = 0.000) 0.64 (0.49, 0.85) 61.3 After childbirth 1.18 (0.60, 2.36) 3.7 Prescott, 2008 1.47 (0.76, 2.86) 3.6 West, 2009 0.43 (0.18, 1.01) 3.0 Jensen, 2012 0.38 (0.07, 2.08) 1.2 Rozé, 2012 0.38 (0.07, 2.08) 1.2 West, 2013 0.61 (0.22, 1.70) 2.4 Loo, 2014 0.73 (0.42, 1.27) 4.4 Schmidt, 2019 0.81 (0.43, 1.55) 3.5 Han, 2019 0.46 (0.23, 0.90) 3.6 Plummer, 2020 2.39 (0.59, 9.79) 1.6 Subgroup, DL (l ² = 44.7%, p = 0.054) 0.93 (0.46, 1.88) 3.6 Before childbirth 0.93 (0.46, 1.88) 3.6 Subgroup, DL (l ² = 59.9%, p = 0.000) 0.72 (0.59, 0.88) 100.0	Rautava 2012	0 17 (0 08 0 35)	3.48
Allen, 2014 0.89 (0.61, 1.30) 5.2 Simpson, 2015 0.89 (0.61, 1.30) 5.2 Ro, 2017 0.30 (0.10, 0.89) 2.3 Wickens, 2018 0.81 (0.50, 1.33) 4.7 Subgroup, DL (l ² = 66.6%, p = 0.000) 0.64 (0.49, 0.85) 61.3 After childbirth 0.64 (0.49, 0.85) 61.3 Taylor, 2007 1.18 (0.60, 2.36) 3.7 Prescott, 2008 1.47 (0.76, 2.86) 3.6 West, 2019 0.43 (0.18, 1.01) 3.0 Jensen, 2012 0.38 (0.07, 2.08) 1.2 Rozé, 2012 0.38 (0.07, 2.08) 1.2 West, 2013 0.61 (0.22, 1.70) 2.4 Loo, 2014 0.73 (0.42, 1.27) 4.3 Schmidt, 2019 0.46 (0.23, 0.90) 3.6 Plummer, 2020 2.39 (0.59, 9.79) 1.6 Subgroup, DL (l ² = 44.7%, p = 0.054) 0.85 (0.62, 1.17) 35.0 Before childbirth 0.93 (0.46, 1.88) 3.6 Subgroup, DL (l ² = 59.9%, p = 0.000) 0.72 (0.59, 0.88) 100.0	Abrahammson 2013	1.06 (0.59, 1.92)	4 21
Nuch, 2017 0.86 (0.57, 1.30) 0.43 Simpson, 2015 0.86 (0.57, 1.30) 5.4 Ro, 2017 0.30 (0.10, 0.89) 2.5 Wickens, 2018 0.81 (0.50, 1.33) 4.7 Subgroup, DL (l ² = 66.6%, p = 0.000) 0.64 (0.49, 0.85) 61.3 After childbirth 1.18 (0.60, 2.36) 3.7 Prescott, 2008 1.47 (0.76, 2.86) 3.6 West, 2009 0.43 (0.18, 1.01) 3.0 Jensen, 2012 2.31 (0.94, 5.64) 2.5 Rozé, 2012 0.38 (0.07, 2.08) 1.2 Vest, 2013 0.61 (0.22, 1.70) 2.4 Loo, 2014 0.73 (0.42, 1.27) 4.3 Cabana, 2017 0.69 (0.38, 1.26) 4.1 Schmidt, 2019 0.81 (0.43, 1.55) 3.9 Plummer, 2020 2.39 (0.59, 9.79) 1.6 Subgroup, DL (l ² = 44.7%, p = 0.054) 0.85 (0.62, 1.17) 35.0 Before childbirth 0.93 (0.46, 1.88) 3.6 Subgroup, DL (l ² = 59.9%, p = 0.000) 0.72 (0.59, 0.88) 100.0	Allen 2014	0.89 (0.61, 1.30)	5.27
Singson, 2017 Subgroup, DL ($l^2 = 66.6\%$, p = 0.000) After childbirth Taylor, 2007 Prescott, 2008 West, 2009 Uest, 2012 Loo, 2014 Cabana, 2017 Subgroup, DL ($l^2 = 44.7\%$, p = 0.054) Before childbirth Boyle, 2011 Subgroup, DL ($l^2 = 44.7\%$, p = 0.054) Before childbirth Boyle, 2011 Subgroup, DL ($l^2 = 59.9\%$, p = 0.000) Oracle 2 Comparison of the sector of t	Simpson 2015	0.86 (0.57, 1.30)	5.11
No. 2017 Wickens, 2018 Subgroup, DL ($l^2 = 66.6\%$, p = 0.000) After childbirth Taylor, 2007 Prescott, 2008 West, 2009 Uest, 2012 Cabana, 2017 Subgroup, DL ($l^2 = 44.7\%$, p = 0.054) Before childbirth Boyle, 2011 Subgroup, DL ($l^2 = 44.7\%$, p = 0.054) Before childbirth Boyle, 2011 Subgroup, DL ($l^2 = 44.7\%$, p = 0.054) Before childbirth Boyle, 2011 Subgroup, DL ($l^2 = 9.9\%$, p = 0.000) 0.0625 0.06215 0.06215 0.06255 0.0000 0.0000 0.00000 0.00000000000000000000000000000000000	Po. 2017	0.30 (0.10, 0.89)	2.11
Witklens, 2010 Subgroup, DL ($l^2 = 66.6\%$, p = 0.000) After childbirth Taylor, 2007 Prescott, 2008 West, 2009 Unserved to the served t	Wickops 2018	0.81 (0.50, 1.33)	4 70
After childbirth Taylor, 2007 Prescott, 2008 West, 2009 Uest, 2012 West, 2012 West, 2013 Loo, 2014 Cabana, 2017 Schmidt, 2019 Plummer, 2020 Subgroup, DL (l ² = 44.7%, p = 0.054) Before childbirth Boyle, 2011 Subgroup, DL (l ² = 44.7%, p = 0.054) Before childbirth Boyle, 2011 Subgroup, DL (l ² = 59.9%, p = 0.000) Overall, DL (l ² = 59.9%, p = 0.000) Overall, DL (l ² = 59.9%, p = 0.000) Cabana, 2017 Subgroup, DL (l ² = 59.9%, p = 0.000) Cabana, 2017 Subgroup, DL (l ² = 59.9%, p = 0.000) Cabana, 2017 Subgroup, DL (l ² = 59.9%, p = 0.000) Cabana, 2017 Subgroup, DL (l ² = 59.9%, p = 0.000) Cabana, 2017 Subgroup, DL (l ² = 59.9%, p = 0.000) Cabana, 2017 Subgroup, DL (l ² = 59.9%, p = 0.000) Cabana, 2017 Subgroup, DL (l ² = 59.9%, p = 0.000) Cabana, 2017 Subgroup, DL (l ² = 59.9%, p = 0.000) Cabana, 2017 Subgroup, DL (l ² = 59.9%, p = 0.000) Cabana, 2017 Subgroup, DL (l ² = 59.9%, p = 0.000) Cabana, 2017 Subgroup, DL (l ² = 59.9%, p = 0.000) Cabana, 2017 Cabana, 2017 Cab	Subgroup $DI_{1}^{12} = 66.60(-p = 0.000)$	0.61 (0.30, 1.33)	61.21
After childbirth Taylor, 2007 Prescott, 2008 West, 2009 Jensen, 2012 Rozé, 2012 West, 2013 Loo, 2014 Cabana, 2017 Schmidt, 2019 Plummer, 2020 Subgroup, DL (l ² = 44.7%, p = 0.054) Before childbirth Boyle, 2011 Subgroup, DL (l ² = 59.9%, p = 0.305 Overall, DL (l ² = 59.9%, p = 0.000) Overall, DL (l ² = 59.9%, p = 0.000) Overall, DL (l ² = 59.9%, p = 0.000) Overall, DL (l ² = 59.9%, p = 0.000) Table Subgroup, DL (l ² = 59.9%, p = 0.000) Overall, DL (l ² =	Subgroup, DE (1 = 00.0%, p = 0.000)	0.04 (0.49, 0.03)	01.51
Taylor, 2007 1.18 (0.60, 2.36) 3.7 Prescott, 2008 1.47 (0.76, 2.86) 3.8 West, 2009 0.43 (0.18, 1.01) 3.0 Jensen, 2012 2.31 (0.94, 5.64) 2.5 Rozé, 2013 0.61 (0.22, 1.70) 2.4 Loo, 2014 0.73 (0.42, 1.27) 4.3 Cabana, 2017 0.69 (0.38, 1.26) 4.1 Schmidt, 2019 0.81 (0.43, 1.55) 3.6 Han, 2019 0.46 (0.23, 0.90) 3.6 Plummer, 2020 2.39 (0.59, 9.79) 1.6 Subgroup, DL (l ² = 44.7%, p = 0.054) 0.85 (0.62, 1.17) 35.0 Before childbirth 0.93 (0.46, 1.88) 3.6 Subgroup, DL (l ² = 0.0%, p = .) 0.93 (0.46, 1.88) 3.6 Heterogeneity between groups: p = 0.355 0.72 (0.59, 0.88) 100.0	After childbirth		
Prescott, 2008 West, 2009 Jensen, 2012 Rozé, 2012 West, 2013 Loo, 2014 Cabana, 2017 Schmidt, 2019 Plummer, 2020 Subgroup, DL (l^2 = 44.7%, p = 0.054) Before childbirth Boyle, 2011 Subgroup, DL (l^2 = 44.7%, p = 0.054) Before childbirth Boyle, 2011 Subgroup, DL (l^2 = 59.9%, p = 0.000) 0.0225 0.0225 1.47 (0.76, 2.86) 0.43 (0.18, 1.01) 2.31 (0.94, 5.64) 2.31 (0.94, 5.64) 2.31 (0.94, 5.64) 2.33 (0.07, 2.08) 1.2 0.38 (0.07, 2.08) 1.2 0.38 (0.07, 2.08) 1.2 0.38 (0.07, 2.08) 1.2 0.38 (0.07, 2.08) 1.2 0.38 (0.07, 2.08) 1.2 0.69 (0.38, 1.26) 0.81 (0.43, 1.55) 0.85 (0.62, 1.17) 35.0 0.93 (0.46, 1.88) 3.6 0.93 (0.46, 1.88) 3.6 0.72 (0.59, 0.88) 100.0	Taylor, 2007	1.18 (0.60, 2.36)	3.73
West, 2009 0.43 (0.18, 1.01) 3.0 Jensen, 2012 2.31 (0.94, 5.64) 2.9 Rozé, 2012 0.61 (0.22, 1.70) 2.4 Uos, 2014 0.73 (0.42, 1.27) 4.3 Cabana, 2017 0.69 (0.38, 1.26) 4.1 Schmidt, 2019 0.81 (0.43, 1.55) 3.6 Plummer, 2020 0.46 (0.23, 0.90) 3.6 Subgroup, DL (I ² = 44.7%, p = 0.054) 0.93 (0.46, 1.88) 3.6 Before childbirth 0.93 (0.46, 1.88) 3.6 Subgroup, DL (I ² = 59.9%, p = 0.000) 0.72 (0.59, 0.88) 100.0	Prescott, 2008	1.47 (0.76, 2.86)	3.84
Jensen, 2012 Rozé, 2012 West, 2013 Loo, 2014 Cabana, 2017 Schmidt, 2019 Plummer, 2020 Subgroup, DL (l ² = 44.7%, p = 0.054) Before childbirth Boyle, 2011 Subgroup, DL (l ² = 0.0%, p = .) Heterogeneity between groups: p = 0.355 Overall, DL (l ² = 59.9%, p = 0.000) D 0625 Loo, 2014 2.31 (0.94, 5.64) 0.38 (0.07, 2.08) 0.61 (0.22, 1.70) 0.61 (0.22, 1.70) 0.69 (0.38, 1.26) 0.69 (0.38, 1.26) 0.69 (0.38, 1.26) 0.61 (0.23, 0.90) 2.39 (0.59, 9.79) 0.85 (0.62, 1.17) 0.93 (0.46, 1.88) 3.66 0.93 (0.46, 1.88) 0.93 (0.46, 1.88) 0.93 (0.46, 1.88) 0.72 (0.59, 0.88) 100.02	West, 2009	0.43 (0.18, 1.01)	3.03
Rozé, 2012 0.38 (0.07, 2.08) 1.2 West, 2013 0.61 (0.22, 1.70) 2.4 Loo, 2014 0.73 (0.42, 1.27) 4.3 Cabana, 2017 0.69 (0.38, 1.26) 4.1 Schmidt, 2019 0.46 (0.23, 0.90) 3.6 Han, 2019 0.46 (0.23, 0.90) 3.6 Plummer, 2020 2.39 (0.59, 9.79) 1.6 Subgroup, DL (I ² = 44.7%, p = 0.054) 0.85 (0.62, 1.17) 35.0 Before childbirth 0.93 (0.46, 1.88) 3.6 Subgroup, DL (I ² = 0.0%, p = .) 0.93 (0.46, 1.88) 3.6 Heterogeneity between groups: p = 0.355 0.72 (0.59, 0.88) 100.0	Jensen, 2012	2.31 (0.94, 5.64)	2.90
West, 2013 Loo, 2014 Cabana, 2017 Schmidt, 2019 Han, 2019 Plummer, 2020 Subgroup, DL (l^2 = 44.7%, p = 0.054) Before childbirth Boyle, 2011 Subgroup, DL (l^2 = 0.0%, p = .) Heterogeneity between groups: p = 0.355 Overall, DL (l^2 = 59.9%, p = 0.000) 0.72 (0.59, 0.88) 100.0	Rozé, 2012	0.38 (0.07, 2.08)	1.20
Loo, 2014 Cabana, 2017 Schmidt, 2019 Han, 2019 Plummer, 2020 Subgroup, DL (l ² = 44.7%, p = 0.054) Before childbirth Boyle, 2011 Subgroup, DL (l ² = 0.0%, p = .) Heterogeneity between groups: p = 0.355 Overall, DL (l ² = 59.9%, p = 0.000) 0.72 (0.59, 0.88) 100.0	West, 2013	0.61 (0.22, 1.70)	2.48
Cabana, 2017 Schmidt, 2019 Han, 2019 Plummer, 2020 Subgroup, DL (l ² = 44.7%, p = 0.054) Before childbirth Boyle, 2011 Subgroup, DL (l ² = 0.0%, p = .) Heterogeneity between groups: p = 0.355 Overall, DL (l ² = 59.9%, p = 0.000) One25 December 201 December 201 Decem	Loo, 2014	0.73 (0.42, 1.27)	4.35
Schmidt, 2019 Han, 2019 Plummer, 2020 Subgroup, DL (l ² = 44.7%, p = 0.054) Before childbirth Boyle, 2011 Subgroup, DL (l ² = 0.0%, p = .) Heterogeneity between groups: p = 0.355 Overall, DL (l ² = 59.9%, p = 0.000) 0.625 16	Cabana, 2017	0.69 (0.38, 1.26)	4.16
Han, 2019 Plummer, 2020 Subgroup, DL (l^2 = 44.7%, p = 0.054) Before childbirth Boyle, 2011 Subgroup, DL (l^2 = 0.0%, p = .) Heterogeneity between groups: p = 0.355 Overall, DL (l^2 = 59.9%, p = 0.000) 0.72 (0.59, 0.88) 100.0 16	Schmidt, 2019	0.81 (0.43, 1.55)	3.93
Plummer, 2020 Subgroup, DL (I ² = 44.7%, p = 0.054) Before childbirth Boyle, 2011 Subgroup, DL (I ² = 0.0%, p = .) Heterogeneity between groups: p = 0.355 Overall, DL (I ² = 59.9%, p = 0.000) 0.72 (0.59, 0.88) 100.0	Han, 2019	0.46 (0.23, 0.90)	3.80
Subgroup, DL (I ² = 44.7%, p = 0.054) Before childbirth Boyle, 2011 Subgroup, DL (I ² = 0.0%, p = .) Heterogeneity between groups: p = 0.355 Overall, DL (I ² = 59.9%, p = 0.000) 0.72 (0.59, 0.88) 100.0	Plummer, 2020	2.39 (0.59, 9.79)	1.60
Before childbirth Boyle, 2011 0.93 (0.46, 1.88) 3.6 Subgroup, DL ($l^2 = 0.0\%$, p = .) 0.93 (0.46, 1.88) 3.6 Heterogeneity between groups: p = 0.355 Overall, DL ($l^2 = 59.9\%$, p = 0.000) 0.72 (0.59, 0.88) 100.6	Subgroup, DL (I ² = 44.7%, p = 0.054)	0.85 (0.62, 1.17)	35.02
Boyle, 2011 Subgroup, DL ($l^2 = 0.0\%$, p = .) Heterogeneity between groups: p = 0.355 Overall, DL ($l^2 = 59.9\%$, p = 0.000) 0.72 (0.59, 0.88) 100.0 16	Before childhirth		
Dayle, 2011 $0.93(0.40, 1.68)$ 3.6 Subgroup, DL (l ² = 0.0%, p = .) $0.93(0.46, 1.88)$ 3.6 Heterogeneity between groups: p = 0.355 $0.72(0.59, 0.88)$ 100.6 0.0625 1 16	Boylo 2011	0.03 (0.46 1.99)	3 66
Heterogeneity between groups: $p = 0.355$ Overall, DL ($l^2 = 59.9\%$, $p = 0.000$) 0.72 (0.59, 0.88) 100.0 1 0.0625 1 1 1 1 1 1 1 1 1 1 1 1 1	Subgroup $DL (l^2 = 0.004 \text{ p} = 1)$	0.93 (0.46, 1.88)	3.00
Heterogeneity between groups: $p = 0.355$ Overall, DL ($l^2 = 59.9\%$, $p = 0.000$) 0.72 (0.59, 0.88) 100.0 0.0625 1	Subgroup, DE (I = 0.0%, p = .)	0.93 (0.40, 1.88)	3.00
Overall, DL (f = 59.9%, p = 0.000)	Heterogeneity between groups: $p = 0.355$		
	Overall, DL (I ² = 59.9%, p = 0.000)	0.72 (0.59, 0.88)	100.00
	0.0625	16	

Figure 4 Subgroup analysis of probiotic interventions for the prevention of atopic dermatitis in children (grouped by timing of the intervention). CI, confidence interval; DL, deep learning.

Europe; meanwhile, when the trial region were Oceania and Asia, the effect of probiotic intervention on the prevention of AD was not significant [RR (95% CI) =0.94 (0.54, 1.61), I^2 =62.6%, $P_{heterogeneity}$ =0.046; RR (95% CI) =0.78 (0.47, 1.31), I^2 =55.7%, $P_{heterogeneity}$ =0.046].

In subgroup analysis on the follow-up time (shown in *Figure 7*), probiotic intervention had a significant effect on the prevention of AD [RR (95% CI) =0.66 (0.51, 0.85)] when the follow-up time was less than 2 years; meanwhile, when the follow-up time was longer than 2 years, the effect

of probiotic intervention on the prevention of AD was not significant [RR (95% CI) =0.95 (0.75, 1.20), I^2 =0.0%, $P_{heterogeneity}$ =0.552].

Evaluation of publication bias and beterogeneity

As shown in *Figure 8*, the publication bias analysis results indicated that the included studies had no obvious publication bias (P=0.433). A Rabe diagram was used to evaluate the heterogeneity of the literature included in

Group 3 and Study	Risk Ratio (95% Cl)	% Weight
Lactobacillus rhamnosus		
Kalliomaki, 2001	0.37 (0.17, 0.77)	3.46
Rautava, 2002	0.20 (0.06, 0.72)	1.84
Kukkonen 2007	0 54 (0 40 0 72)	5 66
Boyle, 2011	0.93 (0.46, 1.88)	3.66
Ou. 2012	1.53 (0.51, 4.58)	2.27
Rautava 2012	0 17 (0 08 0 35)	3 48
Cabana 2017	0.69 (0.38, 1.26)	4 16
Wickens 2018	0.81 (0.50, 1.33)	4.70
Subgroup, DL (l ² = 68.2%, p = 0.003)	0.54 (0.36, 0.80)	29.23
Lactobacillus		
Taylor, 2007	1.18 (0.60, 2.36)	3.73
Bottcher, 2008	1.25 (0.57, 2.76)	3.29
Корр, 2008	1.04 (0.42, 2.57)	2.86
Prescott, 2008	1.47 (0.76, 2.86)	3.84
West, 2009	0.43 (0.18, 1.01)	3.03
Jensen, 2012	2.31 (0.94, 5.64)	2.90
Abrahammson, 2013	1.06 (0.59, 1.92)	4.21
West, 2013	0.61 (0.22, 1.70)	2.48
Subgroup, DL (l ² = 25.7%, p = 0.224)	1.09 (0.79, 1.49)	26.34
mixed probiotics		
Huurre, 2008	0.50 (0.19, 1.36)	2.56
Wickens, 2008	0.53 (0.32, 0.88)	4.63
Niers, 2009	0.34 (0.12, 0.95)	2.42
Dotterud, 2010	♦ 5.14 (1.57, 16.88)	2.04
Kim, 2010	0.43 (0.16, 1.14)	2.62
Rozé, 2012	0.38 (0.07, 2.08)	1.20
Allen, 2014	0.89 (0.61, 1.30)	5.27
Loo, 2014	0.73 (0.42, 1.27)	4.35
Simpson, 2015	0.86 (0.57, 1.30)	5.11
Ro, 2017	0.30 (0.10, 0.89)	2.32
Schmidt, 2019	0.81 (0.43, 1.55)	3.93
Han, 2019	0.46 (0.23, 0.90)	3.80
Plummer, 2020	2.39 (0.59, 9.79)	1.60
Subgroup, DL (l ² = 52.4%, p = 0.014)	0.70 (0.52, 0.93)	41.85
Bifidobacterium		
Wu, 2010	0.58 (0.22, 1.57)	2.58
Subgroup, DL (I* = 0.0%, p = .)	0.58 (0.22, 1.57)	2.58
Heterogeneity between groups: $p = 0.041$ Overall, DL ($l^2 = 59.9\%$, $p = 0.000$)	0.72 (0.59, 0.88)	100.00

Figure 5 Subgroup analysis of probiotic interventions for the prevention of atopic dermatitis in children (grouped by probiotic species). CI, confidence interval; DL, deep learning.

the analysis, and the results are shown in *Figure 9*. The literature was basically distributed according to a straight line, indicating that the heterogeneity was small. However, it is also important to note that there may be errors in the intuitive evaluation through the use of a Rabe diagram. The results of this meta-analysis are generally reliable.

Discussion

In this meta-analysis, we systematically reviewed 37 doubleblind RCTs on the preventive effects of oral probiotics in pregnant women and/or their infants on AD. The results of the analysis showed that probiotics could effectively prevent the incidence of AD. Furthermore, the subgroup analysis results showed that the occurrence of AD could be significantly prevented when mothers and infants took *Lactobacillus rhamnosus* and mixed flora probiotics before and after delivery. Also, studies with follow-up times of less than 2 years and those conducted in Europe found that probiotics were more effective in preventing AD. These findings provide evidence for the efficacy of probiotics in preventing AD in children.

	Risk Ratio	%
Group 4 and Study	(95% CI)	Weight
Europe		
Kalliomaki, 2001	0.37 (0.17, 0.77)	3.46
Rautava, 2002	0.20 (0.06, 0.72)	1.84
Kukkonen, 2007	0.54 (0.40, 0.72)	5.66
Taylor, 2007	1.18 (0.60, 2.36)	3.73
Bottcher, 2008	1.25 (0.57, 2.76)	3.29
Huurre, 2008	0.50 (0.19, 1.36)	2.56
Kopp, 2008	1.04 (0.42, 2.57)	2.86
Niers, 2009	0.34 (0.12, 0.95)	2.42
West 2009	0.43 (0.18, 1.01)	3.03
Dotterud 2010	• <u>5 14 (1 57 16 88)</u>	2 04
Boyle 2011	0.93 (0.46, 1.88)	3 66
Rautava 2012	0 17 (0 08 0 35)	3 48
Rozé 2012	0.38 (0.07, 2.08)	1 20
Abrahammson 2013	1.06 (0.59, 1.92)	4 21
West 2013	0.61 (0.22, 1.70)	2.48
Allen 2014	0.89 (0.61, 1.30)	5.27
Simpson 2015	0.86 (0.57, 1.30)	5.11
	0.60 (0.37, 1.30)	4.16
Po 2017	0.09 (0.36, 1.20)	4.10
Sobmidt 2010	0.30 (0.10, 0.09)	2.32
Schilling, 2019 Subgroup DL $(l^2 = 62.20)$ $r = 0.000)$	0.61 (0.43, 1.33)	3.93
Subgroup, DE (1 - 05.2%, p - 0.000)	0.00 (0.51, 0.00)	00.72
Oceania		
Prescott, 2008	1.47 (0.76, 2.86)	3.84
Wickens, 2008	0.53 (0.32, 0.88)	4.63
Wickens, 2018	0.81 (0.50, 1.33)	4.70
Plummer, 2020	2.39 (0.59, 9.79)	1.60
Subgroup, DL (l ² = 62.6%, p = 0.046)	0.94 (0.54, 1.61)	14.77
Asia		
Kim, 2010	0.43 (0.16, 1.14)	2.62
Wu, 2010	0.58 (0.22, 1.57)	2.58
Jensen, 2012	2.31 (0.94, 5.64)	2.90
Ou, 2012	1.53 (0.51, 4.58)	2.27
Loo, 2014	0.73 (0.42, 1.27)	4.35
Han, 2019	0.46 (0.23, 0.90)	3.80
Subgroup, DL (I ² = 55.7%, p = 0.046)	0.78 (0.47, 1.31)	18.51
Heterogeneity between groups: p = 0.499		
Overall, DL (l ² = 59.9%, p = 0.000)	0.72 (0.59, 0.88)	100.00
0.0625 1	16	

Figure 6 Subgroup analysis of probiotic interventions for the prevention of atopic dermatitis in children (grouped by trial region). CI, confidence interval; DL, deep learning.

In recent years, researchers have gained a better understanding of the physiological functions of human gut microbiota, and gut microbiota have become a research hotspot (51,52). Newborns' first exposure to microbes is provided by the maternal microbiota, and the newborn's gut microbes are influenced by the mode of delivery, type of feeding, and use of antibiotics (53). Colonized gut microbiota is indispensable for intestinal physiological regulation and immune function, and changes in their types and levels may affect the risk of related diseases. According to the definition by the World Health Organization, probiotics are a type of living microorganism, and a certain amount of probiotics can provide benefits to the health of the host (54,55). Probiotics can promote and regulate immune maturation and prevent allergic diseases by regulating the structure of the intestinal microbiota as well as the function of immune cells (56). However, there is still no consensus on the efficacy of probiotics for the clinical prevention and treatment of allergic diseases, and further research is needed. Previous studies have analyzed

	Risk Ratio	%
Group 5 and Study	(95% CI)	Weight
<2 year		
Kalliomaki, 2001	0.37 (0.17, 0.77)	3.46
Rautava, 2002	0.20 (0.06, 0.72)	1.84
Kukkonen, 2007	0.54 (0.40, 0.72)	5.66
Bottcher, 2008	1.25 (0.57, 2.76)	3.29
Huurre, 2008	0.50 (0.19, 1.36)	2.56
Корр, 2008	1.04 (0.42, 2.57)	2.86
Wickens, 2008	0.53 (0.32, 0.88)	4.63
Niers, 2009	0.34 (0.12, 0.95)	2.42
West, 2009	0.43 (0.18, 1.01)	3.03
Dotterud, 2010	5.14 (1.57, 16.88)	2.04
Kim, 2010	0.43 (0.16, 1.14)	2.62
Wu, 2010	0.58 (0.22, 1.57)	2.58
Boyle, 2011	0.93 (0.46, 1.88)	3.66
Jensen, 2012	2.31 (0.94, 5.64)	2.90
Ou, 2012	1.53 (0.51, 4.58)	2.27
Rautava, 2012	0.17 (0.08, 0.35)	3.48
Rozé, 2012	0.38 (0.07, 2.08)	1.20
Allen, 2014	0.89 (0.61, 1.30)	5.27
Cabana, 2017	0.69 (0.38, 1.26)	4.16
Ro, 2017	0.30 (0.10, 0.89)	2.32
Wickens, 2018	0.81 (0.50, 1.33)	4.70
Schmidt, 2019	0.81 (0.43, 1.55)	3.93
Han, 2019	0.46 (0.23, 0.90)	3.80
Plummer, 2020	2.39 (0.59, 9.79)	1.60
Subgroup, DL (l ² = 62.4%, p = 0.000)	0.66 (0.51, 0.85)	76.28
≥2 year		
Taylor, 2007	1.18 (0.60, 2.36)	3.73
Prescott, 2008	1.47 (0.76, 2.86)	3.84
Abrahammson, 2013	1.06 (0.59, 1.92)	4.21
West, 2013	0.61 (0.22, 1.70)	2.48
Loo, 2014	0.73 (0.42, 1.27)	4.35
Simpson, 2015	0.86 (0.57, 1.30)	5.11
Subgroup, DL (l ² = 0.0%, p = 0.552)	0.95 (0.75, 1.20)	23.72
Heterogeneity between groups: p = 0.040		
Overall, DL (l ² = 59.9%, p = 0.000)	0.72 (0.59, 0.88)	100.00
l l 0.0625 1	1 16	

Figure 7 Subgroup analysis of probiotic intervention for the prevention of atopic dermatitis in children (grouped by follow-up time). CI, confidence interval; DL, deep learning.

the efficacy of probiotic intervention in the prevention of AD (1,38,45). However, the sample size of a single study is limited, and confounding factors such as intervention objects, types of probiotics, and appropriate intervention timing were not adjusted. Therefore, this study conducted a meta-analysis of previous studies on the prevention of AD with probiotics, aiming to provide evidence for probiotic intervention in the prevention of AD.

This study found that probiotics could effectively prevent AD [RR (95% CI) =0.83 (0.73, 0.94)], which was basically consistent with previous research results both at home and abroad. Sun *et al.* conducted a meta-analysis of 17 RCTs involving a total of 4,011 children and found that probiotic intervention had a significant benefit in preventing eczema in children [RR (95% CI) =0.59 (0.45, 0.78)] (57). Pan *et al.* conducted a meta-analysis of eight RCTs involving a total of 2,575 newborns and found that probiotics can effectively prevent AD [RR (95% CI) =0.86 (0.78, 0.95)] (58). Probiotics can stimulate intestinal immunoglobulin A (IgA), reduce the adhesion of pathogenic bacteria, and form tight junctions with intestinal epithelial cells to decrease intestinal permeability (59). On the other hand, probiotics can mediate allergic skin inflammation by promoting T helper type 1 (Th1) cytokines, reducing the



Figure 8 Assessment of publication bias. CI, confidence interval.



Figure 9 Rabe plot for heterogeneity assessment.

production of IgE, and decreasing the secretion of Th2 cytokines such as interleukin (IL)-5 and IL-10 (60).

Our subgroup analysis found that probiotic interventions for both mothers and infants had a significant effect on AD prevention when taken at the prenatal and postpartum stages; however, probiotic interventions only for mothers or infants, and only prenatal or postnatal interventions had no significant effect. Maternal microbes are transferred to offspring during pregnancy and can affect immune development and susceptibility to allergic diseases in the offspring (61). Prenatal and postnatal probiotic interventions are beneficial for the prevention of AD in infants. *Lactobacillus rhamnosus* and probiotics with mixed flora have better preventive effects on AD, which may be related to the reduction of intestinal microorganisms such as *Bifidobacterium* and *Lactobacillus* in the intestines of children with AD.

This meta-analysis accounted for the differences in intervention objects, intervention timing, types of probiotics, follow-up time, and trial regions, and carried out subgroup analyses to ensure that the results were detailed and reliable. Yet, there were still some limitations that should be noted. Firstly, we cannot confirm whether there are unpublished relevant data, and there may be some bias in the selection of literature and data extraction. Second, there may be differences in the criteria for AD diagnosis in different studies. In addition, this study did not conduct further subgroup analyses on the dosage of probiotics and the duration of supplementing probiotics.

In conclusion, our study found that probiotics can be an effective means of preventing AD and provide a basis for the clinical prevention of AD. Finally, it cannot be ignored that there is heterogeneity in this study, which may stem from differences in the general characteristics (age, gender, family factors, etc.) of different research subjects, as well as differences in the dosage of probiotics used. Therefore, further research is needed to explore the preventive effect of probiotic intervention on pediatric specific dermatitis in the future.

Conclusions

This study found through meta-analysis that probiotics may be an effective means of preventing AD, and this study can provide a certain degree of basis for the prevention of AD in clinical practice.

Acknowledgments

Funding: None.

Footnote

Reporting Checklist: The authors have completed the PRISMA reporting checklist. Available at https://tp.amegroups.com/article/view/10.21037/tp-23-200/rc

Peer Review File: Available at https://tp.amegroups.com/ article/view/10.21037/tp-23-200/prf

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tp.amegroups. com/article/view/10.21037/tp-23-200/coif). The authors

Wang et al. Probiotics in the prevention of AD in children

746

have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

- 1. Guimarães P, Batista A, Zieger M, et al. Artificial Intelligence in Multiphoton Tomography: Atopic Dermatitis Diagnosis. Sci Rep 2020;10:7968.
- 2. Tokura Y, Hayano S. Subtypes of atopic dermatitis: From phenotype to endotype. Allergol Int 2022;71:14-24.
- Johnson H, Yu J. Current and Emerging Therapies in Pediatric Atopic Dermatitis. Dermatol Ther (Heidelb) 2022;12:2691-703.
- Lockhart MK, Siegfried EC. Evolving Landscape of Systemic Therapy for Pediatric Atopic Dermatitis. Dermatol Clin 2022;40:137-43.
- Mubanga M, Lundholm C, D'Onofrio BM, et al. Association of Early Life Exposure to Antibiotics With Risk of Atopic Dermatitis in Sweden. JAMA Netw Open 2021;4:e215245.
- Naik PP. Recent insights into the management of treatment-resistant pediatric atopic dermatitis. Int J Womens Dermatol 2022;8:e023.
- Khoder G, Al-Yassir F, Al Menhali A, et al. Probiotics Upregulate Trefoil Factors and Downregulate Pepsinogen in the Mouse Stomach. Int J Mol Sci 2019;20:3901.
- Snigdha S, Ha K, Tsai P, et al. Probiotics: Potential novel therapeutics for microbiota-gut-brain axis dysfunction across gender and lifespan. Pharmacol Ther 2022;231:107978.
- Giron M, Thomas M, Dardevet D, et al. Gut microbes and muscle function: can probiotics make our muscles stronger? J Cachexia Sarcopenia Muscle 2022;13:1460-76.
- 10. Compare D, Sgamato C, Nardone OM, et al. Probiotics

in Gastrointestinal Diseases: All that Glitters Is Not Gold. Dig Dis 2022;40:123-32.

- Håkansson Å, Andrén Aronsson C, Brundin C, et al. Effects of Lactobacillus plantarum and Lactobacillus paracasei on the Peripheral Immune Response in Children with Celiac Disease Autoimmunity: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Nutrients 2019;11:1925.
- Ou CY, Kuo HC, Wang L, et al. Prenatal and postnatal probiotics reduces maternal but not childhood allergic diseases: a randomized, double-blind, placebo-controlled trial. Clin Exp Allergy 2012;42:1386-96.
- Schmidt RM, Pilmann Laursen R, Bruun S, et al. Probiotics in late infancy reduce the incidence of eczema: A randomized controlled trial. Pediatr Allergy Immunol 2019;30:335-40.
- Voigt J, Lele M. Lactobacillus rhamnosus Used in the Perinatal Period for the Prevention of Atopic Dermatitis in Infants: A Systematic Review and Meta-Analysis of Randomized Trials. Am J Clin Dermatol 2022;23:801-11.
- 15. Zhou Q, Chen ZH, Zhang JX, et al. A systematic review of the quality of reporting and risk of bias for randomized crossover trials in digestive disease journals. Therap Adv Gastroenterol 2022;15:17562848211067874.
- Abrahamsson TR, Jakobsson T, Björkstén B, et al. No effect of probiotics on respiratory allergies: a seven-year follow-up of a randomized controlled trial in infancy. Pediatr Allergy Immunol 2013;24:556-61.
- Allen SJ, Jordan S, Storey M, et al. Probiotics in the prevention of eczema: a randomised controlled trial. Arch Dis Child 2014;99:1014-9.
- Böttcher MF, Abrahamsson TR, Fredriksson M, et al. Low breast milk TGF-beta2 is induced by Lactobacillus reuteri supplementation and associates with reduced risk of sensitization during infancy. Pediatr Allergy Immunol 2008;19:497-504.
- Boyle RJ, Ismail IH, Kivivuori S, et al. Lactobacillus GG treatment during pregnancy for the prevention of eczema: a randomized controlled trial. Allergy 2011;66:509-16.
- Cabana MD, McKean M, Caughey AB, et al. Early Probiotic Supplementation for Eczema and Asthma Prevention: A Randomized Controlled Trial. Pediatrics 2017;140:e20163000.
- 21. Dotterud CK, Storrø O, Johnsen R, et al. Probiotics in pregnant women to prevent allergic disease: a randomized, double-blind trial. Br J Dermatol 2010;163:616-23.
- 22. Huurre A, Laitinen K, Rautava S, et al. Impact of maternal atopy and probiotic supplementation during pregnancy

Translational Pediatrics, Vol 12, No 4 April 2023

on infant sensitization: a double-blind placebo-controlled study. Clin Exp Allergy 2008;38:1342-8.

- Jensen MP, Meldrum S, Taylor AL, et al. Early probiotic supplementation for allergy prevention: long-term outcomes. J Allergy Clin Immunol 2012;130:1209-1211.e5.
- 24. Kalliomäki M, Salminen S, Arvilommi H, et al. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet 2001;357:1076-9.
- 25. Kalliomäki M, Salminen S, Poussa T, et al. Probiotics and prevention of atopic disease: 4-year followup of a randomised placebo-controlled trial. Lancet 2003;361:1869-71.
- 26. Kalliomäki M, Salminen S, Poussa T, et al. Probiotics during the first 7 years of life: a cumulative risk reduction of eczema in a randomized, placebo-controlled trial. J Allergy Clin Immunol 2007;119:1019-21.
- Kim JY, Kwon JH, Ahn SH, et al. Effect of probiotic mix (Bifidobacterium bifidum, Bifidobacterium lactis, Lactobacillus acidophilus) in the primary prevention of eczema: a double-blind, randomized, placebo-controlled trial. Pediatr Allergy Immunol 2010;21:e386-93.
- Kopp MV, Hennemuth I, Heinzmann A, et al. Randomized, double-blind, placebo-controlled trial of probiotics for primary prevention: no clinical effects of Lactobacillus GG supplementation. Pediatrics 2008;121:e850-6.
- Kuitunen M, Kukkonen K, Juntunen-Backman K, et al. Probiotics prevent IgE-associated allergy until age 5 years in cesarean-delivered children but not in the total cohort. J Allergy Clin Immunol 2009;123:335-41.
- Kukkonen K, Savilahti E, Haahtela T, et al. Probiotics and prebiotic galacto-oligosaccharides in the prevention of allergic diseases: a randomized, double-blind, placebocontrolled trial. J Allergy Clin Immunol 2007;119:192-8.
- 31. Loo EX, Llanora GV, Lu Q, et al. Supplementation with probiotics in the first 6 months of life did not protect against eczema and allergy in at-risk Asian infants: a 5-year follow-up. Int Arch Allergy Immunol 2014;163:25-8.
- Niers L, Martín R, Rijkers G, et al. The effects of selected probiotic strains on the development of eczema (the PandA study). Allergy 2009;64:1349-58.
- Peldan P, Kukkonen AK, Savilahti E, et al. Perinatal probiotics decreased eczema up to 10 years of age, but at 5-10 years, allergic rhino-conjunctivitis was increased. Clin Exp Allergy 2017;47:975-9.
- Plummer EL, Chebar Lozinsky A, Tobin JM, et al. Postnatal probiotics and allergic disease in very preterm infants: Sub-study to the ProPrems randomized trial. Allergy 2020;75:127-36.

- Prescott SL, Wiltschut J, Taylor A, et al. Early markers of allergic disease in a primary prevention study using probiotics: 2.5-year follow-up phase. Allergy 2008;63:1481-90.
- 36. Rautava S, Kainonen E, Salminen S, et al. Maternal probiotic supplementation during pregnancy and breastfeeding reduces the risk of eczema in the infant. J Allergy Clin Immunol 2012;130:1355-60.
- Rautava S, Kalliomäki M, Isolauri E. Probiotics during pregnancy and breast-feeding might confer immunomodulatory protection against atopic disease in the infant. J Allergy Clin Immunol 2002;109:119-21.
- Rø ADB, Simpson MR, Rø TB, et al. Reduced Th22 cell proportion and prevention of atopic dermatitis in infants following maternal probiotic supplementation. Clin Exp Allergy 2017;47:1014-21.
- Rozé JC, Barbarot S, Butel MJ, et al. An α-lactalbuminenriched and symbiotic-supplemented v. a standard infant formula: a multicentre, double-blind, randomised trial. Br J Nutr 2012;107:1616-22.
- Simpson MR, Dotterud CK, Storrø O, et al. Perinatal probiotic supplementation in the prevention of allergy related disease: 6 year follow up of a randomised controlled trial. BMC Dermatol 2015;15:13.
- 41. Taylor AL, Dunstan JA, Prescott SL. Probiotic supplementation for the first 6 months of life fails to reduce the risk of atopic dermatitis and increases the risk of allergen sensitization in high-risk children: a randomized controlled trial. J Allergy Clin Immunol 2007;119:184-91.
- West CE, Hammarström ML, Hernell O. Probiotics during weaning reduce the incidence of eczema. Pediatr Allergy Immunol 2009;20:430-7.
- 43. West CE, Hammarström ML, Hernell O. Probiotics in primary prevention of allergic disease--follow-up at 8-9 years of age. Allergy 2013;68:1015-20.
- 44. Wickens K, Barthow C, Mitchell EA, et al. Effects of Lactobacillus rhamnosus HN001 in early life on the cumulative prevalence of allergic disease to 11 years. Pediatr Allergy Immunol 2018;29:808-14.
- 45. Wickens K, Barthow C, Mitchell EA, et al. Maternal supplementation alone with Lactobacillus rhamnosus HN001 during pregnancy and breastfeeding does not reduce infant eczema. Pediatr Allergy Immunol 2018;29:296-302.
- 46. Wickens K, Black P, Stanley TV, et al. A protective effect of Lactobacillus rhamnosus HN001 against eczema in the first 2 years of life persists to age 4 years. Clin Exp Allergy 2012;42:1071-9.

Wang et al. Probiotics in the prevention of AD in children

- 47. Wickens K, Black PN, Stanley TV, et al. A differential effect of 2 probiotics in the prevention of eczema and atopy: a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol 2008;122:788-94.
- 48. Wickens K, Stanley TV, Mitchell EA, et al. Early supplementation with Lactobacillus rhamnosus HN001 reduces eczema prevalence to 6 years: does it also reduce atopic sensitization? Clin Exp Allergy 2013;43:1048-57.
- Han C. Early application of probiotics in the prevention of neonatal eczema [Master]. Beijing: North China University of Science and Technology, 2019.
- Wu F, Feng X, Liu X, et al. The effect of bifidobacterium on the composition of human milk and its relationship with infant allergic diseases. Journal of Clinical Pediatrics 2010;28:260-3.
- Collado MC, Cernada M, Baüerl C, et al. Microbial ecology and host-microbiota interactions during early life stages. Gut Microbes 2012;3:352-65.
- Sorbara MT, Pamer EG. Microbiome-based therapeutics. Nat Rev Microbiol 2022;20:365-80.
- 53. Lynch SV, Pedersen O. The Human Intestinal Microbiome in Health and Disease. N Engl J Med 2016;375:2369-79.
- Di Mauro A, Neu J, Riezzo G, et al. Gastrointestinal function development and microbiota. Ital J Pediatr 2013;39:15.
- 55. Yadav MK, Kumari I, Singh B, et al. Probiotics, prebiotics and synbiotics: Safe options for next-generation

Cite this article as: Wang F, Wu F, Chen H, Tang B. The effect of probiotics in the prevention of atopic dermatitis in children: a systematic review and meta-analysis. Transl Pediatr 2023;12(4):731-748. doi: 10.21037/tp-23-200

therapeutics. Appl Microbiol Biotechnol 2022;106:505-21.

- Dinan TG, Cryan JF. The Microbiome-Gut-Brain Axis in Health and Disease. Gastroenterol Clin North Am 2017;46:77-89.
- Sun S, Chang G, Zhang L. The prevention effect of probiotics against eczema in children: an update systematic review and meta-analysis. J Dermatolog Treat 2022;33:1844-54.
- Pan H, Su J. Association of Probiotics with Atopic Dermatitis among Infant: A Meta-analysis of Randomized Controlled Trials. Oxid Med Cell Longev 2022;2022:5080190.
- Gibson GR, Hutkins R, Sanders ME, et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol 2017;14:491-502.
- 60. Flinterman AE, Knol EF, van Ieperen-van Dijk AG, et al. Probiotics have a different immunomodulatory potential in vitro versus ex vivo upon oral administration in children with food allergy. Int Arch Allergy Immunol 2007;143:237-44.
- 61. Shen X, Wang M, Zhang X, et al. Dynamic construction of gut microbiota may influence allergic diseases of infants in Southwest China. BMC Microbiol 2019;19:123.

(English Language Editor: A. Kassem)

748